AB Science
Researches and develops protein kinase inhibitors for human and veterinary medicine.
AB | PA
Overview
Corporate Details
- ISIN(s):
- FR0010557264 (+1 more)
- LEI:
- 969500U43TVR8CCVBJ97
- Country:
- France
- Address:
- 3 AVENUE GEORGE V, 75008 PARIS
- Website:
- https://www.ab-science.com
- Sector:
- Manufacturing
Description
AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-18 19:17 |
AB Science announces the initiation of coverage of its stock by Maxim Group wit…
|
English | 200.2 KB | ||
| 2025-12-18 19:17 |
AB Science annonce l’initiation de la couverture de son titre par Maxim Group a…
|
French | 202.2 KB | ||
| 2025-12-15 18:39 |
AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comm…
|
French | 291.3 KB | ||
| 2025-12-15 18:39 |
AB Science announces a new publication on biorxiv that identifies AB8939 as a p…
|
English | 290.4 KB | ||
| 2025-12-11 18:29 |
AB Science announces new publication on Medrxiv highlighting clinical benefit w…
|
English | 255.0 KB | ||
| 2025-12-11 18:29 |
AB Science annonce une nouvelle publication sur Medrxiv mettant en évidence le …
|
French | 252.5 KB | ||
| 2025-09-30 18:32 |
AB Science annonce annonce un léger décalage de la publication de son rapport f…
|
French | 165.7 KB | ||
| 2025-09-30 18:32 |
AB Science announces a slight delay in the publication of its 2025 half-year fi…
|
English | 192.5 KB | ||
| 2025-08-04 07:58 |
AB Science annonce le succès d’un placement privé d’environ 2,55 millions d’eur…
|
French | 332.3 KB | ||
| 2025-08-04 07:58 |
AB Science announces the successful completion of a 2.55 million euros private …
|
English | 323.2 KB | ||
| 2025-07-24 07:56 |
AB Science has received approval from several European countries to initiate th…
|
English | 297.9 KB | ||
| 2025-07-24 07:56 |
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’é…
|
French | 273.3 KB | ||
| 2025-06-23 08:03 |
AB Science - New peer-reviewed data provide strong evidence supporting masitini…
|
English | 307.5 KB | ||
| 2025-06-23 08:03 |
AB Science - De nouvelles données évaluées par des pairs apportent des preuves …
|
French | 290.6 KB | ||
| 2025-06-12 07:59 |
AB Science annonce la délivrance d’un brevet canadien protégeant la composition…
|
French | 197.9 KB |
Automate Your Workflow. Get a real-time feed of all AB Science filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AB Science
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AB Science via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
